Suppression of estrogen-withdrawal headache with extended transdermal contraception
Katherine D LaGuardia, Alan C Fisher, James D Bainbridge, John M LoCoco, Andrew J Friedman, Katherine D LaGuardia, Alan C Fisher, James D Bainbridge, John M LoCoco, Andrew J Friedman
Abstract
A randomized clinical trial was conducted with 239 women at nine clinical research sites to compare bleeding profile, headache frequency, and subject satisfaction with the transdermal contraceptive, ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system) used in an extended regimen (84 days) with a traditional, 28-day cyclic regimen. In a majority of women studied, compared with cyclic use, extended use of transdermal norelgestromin/ethinyl estradiol delayed menses and reduced the total incidence of mean headache days during the hormone-free interval.
Source: PubMed